nicergoline

Trade name: Sermion

Small moleculeexperimental

Nicergoline, sold under the brand name Sermion among others, is an ergot derivative used to treat senile dementia and other disorders with vascular origins. Internationally it has been used for frontotemporal dementia as well as early onset in Lewy body dementia and Parkinson's dementia. It decreases vascular resistance and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells. It has similar vasoactive properties in other areas of the body, particularly the lungs. Unlike many other ergolines, such as ergotamine, nicergoline is not associated with cardiac fibrosis. — Wikipedia

Clinical trial activity

2 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Dec 23, 2019 (NCT04176367)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05551182Phase 3Jan 31, 2023Burapha University, Government of Thailand, Silpakorn University
NCT04176367Phase 1Dec 23, 2019Pfizer
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Burapha UniversityAcademic/Hospital1012023
Government of ThailandGovernment1112023
PfizerFor profit1112019
Silpakorn UniversityAcademic/Hospital1012023
4 organizations
Page 1 / 1